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Abstract 
Purpose: To report the clinical and ultrasound features and outcomes of a series of nodular 
posterior scleritis.  
  
Methods: Retrospective medical record review of 11 consecutive patients with nodular 
posterior scleritis. Patient demographics, ocular and systemic findings, ultrasound features 
and final anatomical and visual outcomes were recorded. 
 
Results: There were 9 females and 2 males (11 eyes) with mean age at presentation of 57 
years (range 30-84 years).  Underlying systemic inflammatory disease was present in 73%.  
Symptoms included pain in 73% and blurred vision in 45%.  A solitary amelanotic mass 
without the presence of lipofuscin was found in all cases. Associated ocular features 
included retinal pigment epithelial changes (67%), intraocular inflammation (55%), subretinal 
fluid (50%), macular edema (50%) and choroidal folds (30%). B-Mode ultrasound showed a 
high internal reflectivity sclerochoroidal mass (100%) with mean elevation of 4.1 mm. There 
was nodular thickening of the sclera (100%) and fluid in Tenon’s space or ‘T’ sign (36%). A 
complete regression of the nodule after the treatment was observed only in one patient (11 
%), and partial regression in 4 patients (44 %). 
 
Conclusion: Nodular posterior scleritis should be considered in the differential diagnosis of a 
single amelanotic choroidal mass showing high internal reflectivity on ultrasound B-scan. It 
can produce intraocular inflammation in 50% of the cases and may be painless in 25%. It 
has a high association with a systemic underlying disease.  
 
Keywords: Choroidal mass lesion, Masquerade syndrome, Nodular posterior scleritis, 
Posterior scleritis, Pseudomelanoma, Ultrasound 
 
Summary statement 
We report the clinical and ultrasound features and outcomes of a series of nodular posterior 
scleritis. It should be considered as one of the differential diagnosis for choroidal mass 
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lesion. Based on our observations in 11 cases and review of the reports in the literature a 
proposed diagnostic criteria for posterior nodular scleritis are presented.  
 
“This work was supported by the National Institute for Health Research (NIHR) Biomedical 
Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute 
of Ophthalmology. The views expressed are those of the author(s) and not necessarily those 
of the NHS, the NIHR or the Department of Health.” None of the authors have any financial 
or conflicting interests to disclose. 
 
Introduction 
The presence of a mass lesion in the choroid has a wide differential diagnosis, including 
tumours and pseudotumours. Among the pseudotumours, posterior scleritis is a scleral 
inflammatory disease which may lead to the formation of a choroidal mass and can be the 
result of an infectious process, trauma, prior ocular surgery, associated systemic disease or 
can be idiopathic.  
 
Posterior scleritis has two clinical and sonographic forms: diffuse and nodular.1 In the diffuse 
type, there is generalised thickening of posterior sclera, usually most obvious temporally. 
Localised nodular thickening of the eye coats is exceedingly rare and only sporadic case 
reports are published in the literature. 2–5 The first  reported case suspecting nodular 
involvement was described in 1915 by Derby, in a patient with brawny scleritis with massive 
granuloma of the sclera.2 Clinically such a choroidal mass can masquerade as a choroidal 
melanoma, lymphoma, metastatic deposit or hemangioma. Its clinical differential diagnosis 
from choroidal tumours is sometimes difficult and occasionaly a chorioretinal biopsy is 
needed.3  Inappropriate diagnosis can lead to erroneous invasive diagnostic tests and 
treatment and there are reports of enucleation due to suspicion  of a choroidal malignant 
melanoma.4,5 
 
The present study aims to describe the patient characteristics, systemic associations, clinical 
and ultrasound features and outcomes of a large series of patients with posterior nodular 
scleritis.  
 
Methods 
The medical records of patients with nodular posterior scleritis presenting to a tertiary 
referral centre in the UK from January 2001 to March 2014 were reviewed. This study 
adhered to the tenets of the Declaration of Helsinki and was conducted after obtaining 
institutional review board approval for retrospective analysis of data (ROAD 14/003).   
 
Patient demographics, ocular and systemic findings, ultrasound features, ocular and 
systemic treatments and final anatomical and visual outcomes were recorded. All patients 
underwent detailed anterior and posterior segment slit-lamp and ultrasound examination. 
Fluorescein angiography (FA) and optical coherence tomography (OCT) was performed as 
needed to establish the diagnosis.  The follow-up period and complications were 
documented. 
 
The ultrasound examinations were carried out by one author (M.R.) using the whole body 
Siemens Acuson 512 scanner and the probes used were the 15L8 and 10V4. The findings 
recorded included location, shape, reflectivity and height of the lesion, number of lobes, 
associated subretinal fluid, choroidal excavation and extraocular features (myositis, mass in 
orbit, ‘T’ sign of fluid in sub-Tenon’s space). A lesion shape was described as sessile when 
the ratio of base to maximal elevation was ≥ 7:1. A dome shaped lesion  had a curved 
anterior surface, minimum elevation at the base edges  and with a base to 
maximal  elevation  ratio < 7:1. Regression of the clinical and ultrasound signs for the nodule 
at different follow-up visits was also recorded. 
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Results 
During a 13 year period (2001-2014), there were 11 patients, (9 female and 2 male) with 
posterior nodular scleritis presenting to our department. The mean age (± SD) at 
presentation was 57 (±17) years (median 60, range 30 to 84 years). There were no 
asymptomatic cases at presentation. The most common symptom was pain (8 eyes, 73 %), 
followed by blurred vision (5 eyes, 45 %) and headache (1 patient, 9 %). In almost half the 
patients the referring diagnosis was choroidal mass (5 eyes, 45 %), followed by posterior 
scleritis (3 eyes, 27 %), and 1 eye (9%) each of lymphoma, vasculitis and uveitis. There was 
a family history of breast cancer in 1 patient and lung cancer in another. In 5 patients, there 
was associated systemic inflammatory disease (arthritis, ulcerative colitis, temporal arteritis, 
Wegener’s granulomatosis) and in 3 patients there was a prior history of ocular inflammation 
(uveitis and bilateral retinal vasculitis). The mean follow up period (±SD) was 50 (± 48) 
months (range 5-146 months).  
 
The clinical features are summarised in Table 1. In all cases the disease was unilateral. The 
mean logMAR visual acuity (±SD) at presentation was 0.75 (±1.05). Out of 11 patients, 7 
had a red eye on examination (64 %). There was associated anterior scleritis in 4 eyes (36 
%) and anterior uveitis in 6 eyes (55 %).  Examination of the fundus was not possible in 1 
eye, due to corneal decompensation and in 1 eye, the fundus examination appeared normal, 
but the nodular component was found on B-Mode ultrasound testing.  Therefore, in 9 
patients a choroidal mass was seen clinically on fundus examination (Figure 1). All nodules 
were non-pigmented without the presence of lipofuscin or drusen. Other features included 
choroidal folds in 3 eyes (30%), subretinal fluid in 5 eyes (50%), macular edema in 5 eyes 
(50%) and retinal pigment epithelial changes in 6 eyes (67%). There were 5 patients that 
required ocular oncology review in order to exclude possible ocular malignancy. Two of 
these underwent chorioretinal biopsy with histology report showing no signs of neoplasia 
and consistent with reactive inflammatory process.  
 
On ocular B-Mode ultrasound all lesions were solitary, had high internal reflectivity and no 
internal blood flow. (Table 2). The shape of the mass was sessile in 7 eyes (64 %) and dome 
shaped in 4 eyes (36 %). There were no collar stud shaped lesions and choroidal excavation 
was also absent in all cases (Figure 2). Subretinal fluid was detected in 3 eyes (27 %) and 
fluid was found in Tenon’s space (‘T’ sign) in 4 eyes (36 %).  During the follow-up period, 1 
eye developed choroidal effusion and 1 eye had choroidal effusion with total retinal 
detachment. The mean baseline thickness of the scleral nodule (± SD) was 4.1 (± 2.1) mm 
(range: 2.1 to 8.6 mm). Ultrasound was used as a follow up tool to assess and monitor the 
progression of the lesion (Figure 3). 
 
FA and OCT scans were used as required to assist the diagnosis in 5 and 3 eyes respectively. 
(Figure 4 and Figure 5). FA features included staining of the lesion (4 eyes) in the late phase, 
optic disc leakage (4 eyes), angiographic macular edema (4 eyes) and leakage from retinal 
vessels (1 eye). The fellow eye was normal on FA in 3 out of 5 cases, whereas 2 fellow eyes 
had disc staining and cystoid macular oedema. A fellow eye was affected in one patient with 
bilateral vasculitis and in a patient with Wegener’s granulomatosis. In the 3 eyes that 
underwent OCT, it was possible to scan the nodule in 2 eyes. Features on OCT scan included 
cystoid macular oedema in 2 eyes, loss of ellipsoid layer over the lesion in 2 eyes, 
hypereflective retinal epithelial irregularity in 2 eyes or hypereflective subretinal thickening 1 
eye. 
 
Laboratory workup included chest x-ray, complete blood count, angiotensin-converting 
enzyme (ACE), QuantiFERONR-TB Gold test, venereal disease research laboratory (VDRL) 
test, antinuclear antibody (ANA), rheumatoid factor (RF), anti-neutrophil cytoplasmic antibody 
(ANCA). ANA was positive in 2 patients (18 %), RF in one (9 %) and cytoplasmic-ANCA (c-
ANCA) in one patient (9 %). All other tests were normal. Other systemic tests included 
mammography and Positron Emission Tomography – Computed Tomography (PET-CT) to 
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rule out a metastatic deposit from breast cancer as there was a strong family history. There 
was no metabolic activity detected on PET scan. One patient had magnetic resonance 
imaging (MRI) of the orbit. 
 
Local treatment included topical steroids alone (36 %) or in combination with steroidal anti-
inflammatory drugs (NSAIDs) in 36 % and subTenon steroid injection in in 18%. Systemic 
NSAIDs were used in 45 %. In patients non-responsive to oral NSAIDs and those with more 
severe presentation, systemic steroids were used. Oral corticosteroids were used in 82 % of 
cases and in 36 % immunosuppressive agents were required to control the disease.  
 
Total regression of the nodule was observed only in one patient (11 %) and partial 
regression in 4 (44 %) patients. Documented growth by clinical examination or interval B-
mode ultrasound scans was not apparent in any case. However, on B scan a fluctuation of 
scleral thickness was commonly observed. Figure 3 shows regression of the nodule on B-
mode ultrasound scans in one case that had a follow up of 146 months. Local complications 
included cataract (27 %), glaucoma (18 %) and epiretinal membrane formation (18 %). 
Systemic complications were osteoporosis, diabetes and chronic pain in 9 % each. 
 
Discussion 
Nodular posterior scleritis is an important but benign ocular disorder, that can pose a 
diagnostic conundrum. It is rare, as demonstrated in the series of Shields et al.7 In that 
report, out of 400 intraocular tumours and pseudotumours, only 1.5 % were nodular scleritis, 
the remainder the eyes were 27% with choroidal naevus, 13% with age related macular 
degeneration, 11% with extramacular age related macular degeneration, 10% with 
congenital hypertrophy of the retinal pigment epithelium and  8% with choroidal 
haemangioma. Scleritis can be diffuse, but the more unusual nodular type masquerades as 
an intraocular tumour, and is a discrete thickened sclerochoridal area. Presenting 
symptoms, clinical and imaging features, especially ultrasound can help to differentiate 
nodular posterior scleritis from other pathology to allow optimal treatment, and importantly to 
avoid erroneous management. In the current study we aim to add to the literature our 
experience of a large series of nodular posterior scleritis, to detail the diagnostic features for 
this unique entity. 
 
In our study, the majority of patients diagnosed with nodular posterior scleritis were female 
(82%). This agrees with the the literature on posterior scleritis1 as well as its association with 
systemic inflammatory diseases. The most common associated systemic disease in 
posterior scleritis patients is rheumatiod arthritis 1,6 and this was confirmed in our series of 
the posterior nodular variant (18 %). Pain is a key presenting symptom in patients with 
scleritis, but may be absent in posterior scleritis. In choroidal tumours such as melanoma, 
retinal symptoms such as photopsiae or blurred vision predominate. However, intraocular 
tumours can cause an inflammatory reaction. For example, necrotic choroidal melanomas 
are  associated with episcleritis and scleritis, and can be painful.8 In our series important 
clinical clues to the true diagnosis included associated anterior scleritis (36 %), anterior 
chamber or vitreous inflammation (55% and 40%), suggesting inflammatory eye disease. 
Other characteristic fundus features included choroidal folds (30%), subretinal fluid (50%) 
and cystoid macular oedema (50%).  
 
The real challenge comes in differentiating this benign sclero-choroidal mass or lesion from 
a malignant one. In addition to demographic profile and presenting history, the clinical and 
ultraosonographic characteristics of the mass help to establish a diagnosis in favour of 
nodular posterior scleritis. Choroidal melanoma usually has a dome or collar stud shape, the 
latter occurring when the tumour ruptures Bruch’s membrane. None of our cases had a 
collar stud shape and the predominant shape noted in our cohort was sessile (63%). Other 
tumours such as metastatic deposits or choroidal lymphoma can be bilobed or multilobed. In 
contrast, all our cases were a solitary nodule.  
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The colour of the mass in nodular posterior scleritis was pale in all cases in our series.  
Choroidal melanomas are pigmented in 85%, but the remainder are non-pigmented tumours. 
Furthermore, lipofuscin which is one of the five risk factors of growth and a hallmark for 
melanoma, 9 was a feature that was absent in all our patients with nodular posterior scleritis. 
Commonly encountered pale tumours include metastatic deposits. These tend to have a 
larger amount of subretinal fluid than nodular posterior scleritis, and in two-thirds of cases, 
the primary malignancy is known.10 
 
Optic disc oedema is reported in posterior scleritis in upto  45%,1,11  but this was not 
detected in our patients. Possible reasons for this include a less widespread inflammatory 
pathology for this nodular type of scleritis as compared to diffuse scleritis and a location in all 
but 1 eye away from the juxtapapillary location. 
 
Choroidal lymphoma (previously termed benign reactive lymphoid hyperplasia) is a low 
grade MALT (mucosa-associated lymphoid tissue) type lymphoproliferative disorder. 12   It 
presents with a unilateral amelanoic mass with diffuse or nodular appearance that can mimic 
nodular scleritis. Occasionally subretinal fluid is found or infiltration of anterior uveal tract, 
but often there is a subconjunctival salmon patch, that is readiliy biopsied to make the 
diagnosis.  In choroidal MALT lymphoma, ultrasound B-scan finds choroidal thickening, often 
with an extraocular extension, with typically low to medium internal reflectivity and internal 
vascularity.12  This is different to nodular posterior scleritis, where there is thickened sclero-
choroidal tissue exhibiting high internal reflectivity. 
 
B-Mode ultrasound scan is the key investigation in the workup of posterior segment tumours 
and pseudotumours. In the Collaborative Ocular Melanoma Study (COMS), 88% of choroidal 
melanomas had mixed echogenicity with mainly medium and low amplitude echoes, a collar 
stud shape or both features.13 In our nodular posterior scleritis series, all eyes had a sessile 
or dome shaped lesion. There was absence of choroidal excavation in all eyes. Oedema in 
Tenon’s space (‘T’ sign) indicating an inflammatory aetiology was present in 36%, in 
agreement with other reports.5 Choroidal effusion, also reported in posterior scleritis,1 was 
detected in 18% of our cases.  
 
The differential diagnosis of a pale choroidal elevation with high internal refectivity on B-scan 
includes choroidal metastasis, choroidal haemangioma and posterior nodular scleritis. The 
latter has been reported to simulate choroidal metastasis.14 In 520 cases with uveal 
metastases, choroidal metastases were yellow, plateau shaped and had subretinal fluid.15  
In that report, 92% of metastases were found in locations posterior to the equator and two-
thirds of patients had a previous diagnosis of systemic cancer. Often the retinal detachement 
is greater in active matastatic deposits than posterior nodular scleritis. Choroidal 
haemangiomas have high internal reflectivity on B-scan, and often present with visual loss 
from an exudative retinal detachment.16 On B-scan, there is usually fast internal blood flow 
to distinguish these from nodular posterior scleritis, and indocyanine green angiography and 
enhanced depth spectral domain OCT is useful in the diagnosis of choroidal haemangiomas. 
 
Fluorescein angiograpy performed in 5 patients showed evidence of inflammation with disc 
staining (80%) and macular oedema (80%) and vasculitis (20%). No cases demonstrated 
the dual circulation sign that is associated with choroidal melanomas. OCT was of limited 
use in posterior noodular scleritis due to size and location of the thickening, but was helpful 
in confirming cystoid macular oedema. 
 
Magnetic resonance imaging has been reported as additional diagnostic tool in 
differentiating posterior nodular scleritis from choroidal melanoma.3 It was required in only 1 
case in our series, where thickenning and enhancement of sclera was found. Earlier reports 
have shown magnetic resonance imaging can be helpful in larger tumors (>2mm thick) and 
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shows presence of low signal in comparison to vitreous in both T1 and T2-weighted 
images.17 In melanoma, MRI scans usually show a high signal on T1-weighted images and a 
low signal on T2 weighted images.18  
 
Choroidal biopsy is a valuable diagnostic procedure in patients with suspected malignant or 
inflammatory origin of the lesion.19 Two cases in the current study required this to exclude 
suspected lymphoma in one patient and a malignant choroidal tumour in the other.  A few 
reports describe scleral3,20 or vitrectomy-assisted biopsy19,21 as diagnostic tool to obtain 
histolopathological diagnosis of  scleritis. Though biopsy can be conclusive, the risk involved 
with the invasive nature of the procedure, should leave it as an option only for cases where 
the diagnosis remains uncertain despite non-invasive testing.   
 
Different treatment options were explored including topical therapy with corticosteroids 
and/or NSAIDs, periocular adjuvant therapy with depot steroids, systemic corticosteroids 
and immunosuppressive agents for varying periods of time.  Systemic immunosuppressive 
agents tried included Mycophenolate mofetil, Azathioprine, Cyclophospamide, Rituximab 
and Methotrexate. The inflammation and pain associated with scleritis improved with 
treatment. However, contrary to published reports, no treatment led to complete resolution of 
the nodule, only a reduction in its size. Other reports20,22 of isolated cases or small series 
have shown that steroid treatment resolved the nodule completely. In the current series, 
symptoms resolved, inflammatory signs reduced, but a nodule persisited in all but one eye 
(89%).  
 
An interesting finding was fluctuation of nodule thickness during observation, possibly 
reflecting disease activity.   Demirci et al3 reported a stable nodule even without any 
treatment during 12 years of follow up. Often systemic steroids and NSAIDs are used in 
posterior scleritis patients, sometimes in combination with local topical or periocular 
treatment. Use of immunosupressive agents is reported to be required between 24 %11 and 
85 %.23  Four patients (36 %) in this study with observed fluctuation of the scleral nodule 
thickness despite steroid treatment needed immunosuppressive medication to control 
activity. In all cases regression or stability of the scleral nodule on ultrasound was observed 
after the treatment with mean final elevation of 3.4 mm measured with ultrasound. In two 
patients treatment was stopped after recovery of symptoms and no growth of the residual 
scleral nodule was observed after a follow-up of 20 months in one patient and 6 months in 
the second patient.  Therefore once the inflammatory symptoms and signs have resolved, a 
stable residual nodule may be persist, and on its own doen not merit additional treatment. 
 
A literature review of publications, summarized in Table 3, revealed reports of isolated cases 
or small series with posterior nodualr scleritis, 3,5,14,20,22,24–27 stimulating the present study to 
evaluate the features of our series. In the published reports, most of the cases were adult 
females with a unilateral yellow-orange subretinal or choroidal mass with subretinal fluid or 
choroidal folds, in agreement with our results. Only Kranias et al27 reported bilateral 
sequential choroidal masses, occurring 41 months apart. Optic disc edema was present in 2 
cases.24,26 In the reports there were 2 cases5,20 out of 10 that had associated systemic 
disease, whereas in the present study, there were 5 out of 11 that had associated 
inflammatory disease. On ultrasound B-scan the common features were a nodule of medium 
to high internal echogenicity, with ‘T’ sign in 70%. In contrast, we found a ‘T’ sign on B-scan 
in only 36 %. Furthermore, most cases in the literature show complete resolution of the 
mass with steroid treatment, whereas we found it was common to observe a fluctuating 
nodule. 
  
Based on our observations in 11 cases and review of the reports in the literature (Table 3), 
clinical characteristics of nodular posterior scleritis include (Table 4): strong female 
preponderance; strictly unilateral; pain (but not always); associated systemic inflammatory 
disease; Intraocular inflammatory signs; solitary, non-pigmented subretinal mass with 
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choroidal folds and absence of lipofuscin. Ultrasound features are of sessile, unilobed lesion 
with high reflectivity and oedema in sub-Tenon’s space. (‘T’ sign).  Fluorescein angiography 
may confirm inflammatory origin with optic disc staining and macular oedema, and will also 
exclude dual circulation. It is important to recognize these features to diagnose nodular 
posterior scleritis and to realize that this entity responds to therapy although a residual 
scleral nodule may persist. 
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Figure legends 
Figure 1: Color fundus photos of choroidal lesions. Fig 1A and 1B shows elevated solitary 
subretinal lesion. Fig 1C shows solitary irregular greyish white well defined lesion at 
subretinal level with no pigmentation and no lipofuscin. Fig 1D: presence of elevated 
amleanotic choroidal lesion.  
Figure 2:  Ultrasonographic chracteristics of the nodular posterior scleritis and adjacent 
normal ocular coats. 2A: Transverse B-Mode image of nasal scleral nodule (thickness: 
3.5mm). 2B: Transverse B-Mode image of nasal scleral nodule (thickness: 6.6 mm). 2C: 
Transverse B-Mode image of inferior scleral nodule (thickness: 7.3mm). 2D: same eye as 
Fig 2C in longitudinal B-Mode image showing inferior nodule (cursors).  
Figure 3: Representative follow up ultrasound images of two of the eleven patients with 
posterior nodular scleritis.  
3A: (a-d) Nasal nodular scleritis: Transverse B-Mode images showing reduction in 
thickness of nodule over time. Thickness - (a): July 2011 - 7.5mm, (b): September 2011-
3.2mm, (c): January 2012 - 2.6mm, (d) October 2012 - 2.3mm.  
3B: (a-d): Inferior nodular scleritis: Longitudinal B-Mode images taken on same eye with 
inferior gaze.  Images taken at different time period over a 4 year period. Thickness - (a) 
2008: 7.5mm (b) 2009: 5.4   mm, (c) 2010: 6.9mm, (d) 2011: 5.3mm 
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Figure 4: Fundus fluorescein angiograhic findings in patients with posterior nodular scleritis. 
Fig 4A shows presence of macular edema. Fig 4B demonstrates presence of aniographic 
macular edema with presence of staining of the choroidal lesion inferotemporal to macula.  
 Figure 5: OCT findings in patients with posterior nodular scleritis. Spectralis OCT 
demonstrates presence of hyperrelflecitve RPE irregularity (Fig 5A) and presence of 
subretinal fluid (Fig 5B) 
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Tables 
Table 1. Clinical features and systemic investigations 
Feature Number of patients (%) 
Laterality  
  Unilateral 11 (100) 
Initial visual acuity  
  6/6 (20/20) 4 (36) 
  6/7.5  - 6/12 (20/25 – 20/40) 1 (9) 
  6/15 - 6/48 (20/50 – 20/160) 3 (27) 
  6/60 (20/200) or worse 3 (27) 
Anterior segment findings (n = 11 patients)  
  Proptosis, reduced motility 0 
  Conjunctival injection, chemosis 7 (64) 
  Peripheral keratitis 0 
  Corneal decompensation 1 (9) 
  Flare 3 (27) 
  Anterior scleritis 4 (36) 
  Anterior uveitis 6 (54) 
  Glaucoma, ocular hypertension 2 (18) 
Posterior segment findings (n = 10 
patients) 
 
Vitreous cells 4 (40) 
Choroidal folds, retinal striae 3 (30) 
Annular choroidal detachment 1* (10) 
Retinal detacment  
  Total 1* (10) 
  Subtotal 0 
  No RD 9 (90) 
Non-RD subretinal fluid  
  Clinical 4 (40) 
  On OCT 1 (10) 
  None 5 (50) 
Macular oedema 5 (50) 
Macular star 0 
Optic nerve swelling 0 
Vasculitis 1 (10) 
Choroidal mass features ( n = 9 patients)†  
Location  
  Inferotemporal 4 (36) 
  Inferior        2 (18) 
  Superonasal 3 (27) 
  Inferonasal 2 (18) 
Colour  
  Nonpigmented 9 (100) 
  Pigmented 0 
Position of apex  
  Macular 0 
  Juxtapapillary 1 (11) 
  Equatorial 8 (89) 
Lipofuscin 0 
Drusen 0 
RPE changes 6 (67) 
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RD – retinal detachment; OCT - optical coherence tomography 
* During follow-up 
† - In 9 choroidal mass was seen clinically (in 1 eye fundus was not visible due to corneal 
decompensation; in 1 eye nodular scleritis was detected only on ultrasound) 
 
Table 2: Ocular ultrasound findings  
 
Feature Number of patients (%) 
Shape  
  Dome  4 (36) 
  Sessile 7 (64) 
Number of lobes  
  One 11 (100) 
Reflectivity  
  High 11 (100) 
  Medium 0 
  Low 0 
Subretinal fluid 3 (27.3) 
Choroidal excavation 0 
Extraocular features  
  Mass in orbit 0 
  T sign 4 (36) 
Other  
  Choroidal effusion 1 (9)* 
  Choroidal effusion with retinal detachment 1 (9)* 
Baseline elevation of the lesion (mm)  
  Mean ± SD 4.1 ± 2.1 
  Median (range) 3.5 (2.1-8.6) 
Final elevation of the lesion (mm)  
  Mean ± SD 3.4 ± 1.7 
  Median (range) 3.1 (1.9-6.9) 
 
* During follow-up 
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Figure 1: Color fundus photos of choroidal lesions. Fig 1A and 1B shows elevated solitary 
subretinal lesion. Fig 1C shows solitary irregular greyish white well defined lesion at 
subretinal level with no pigmentation and no lipofuscin. Fig 1D: presence of elevated 
amleanotic choroidal lesion. 
 
 
 
Figure 2:  Ultrasonographic chracteristics of the nodular posterior scleritis and adjacent 
normal ocular coats. 2A: Transverse B-Mode image of nasal scleral nodule (thickness: 
3.5mm). 2B: Transverse B-Mode image of nasal scleral nodule (thickness: 6.6 mm). 2C: 
Transverse B-Mode image of inferior scleral nodule (thickness: 7.3mm). 2D: same eye as 
Fig 2C in longitudinal B-Mode image showing inferior nodule (cursors).  
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Figure 3: Representative follow up ultrasound images of two of the eleven patients with 
posterior nodular scleritis.  
3A: (a-d) Nasal nodular scleritis : Transverse B-Mode images showing reduction in 
thickness of nodule over time. Thickness - (a): July 2011 - 7.5mm, (b): September 2011-
3.2mm, (c): January 2012 - 2.6mm, (d) October 2012 - 2.3mm. 3B: (a-d): Inferior nodular 
scleritis: Longitudinal B-Mode images taken on same eye with inferior gaze.  Images taken 
at different time period over a 4 year period. Thickness - (a) 2008: 7.5mm (b) 2009: 5.4   
mm, (c) 2010: 6.9mm, (d) 2011: 5.3mm 
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Figure 4: Fundus fluorescein angiograhic findings in patients with posterior nodular scleritis. 
Fig 4A shows presence of macular edema. Fig 4B demonstrates presence of aniographic 
macular edema with pesence of staining of the choroidal lesion inferotemporal to macula.  
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Figure 5: OCT findings in patients with posterior nodular scleritis. Spectralis OCT 
demonstrates presence of  hyperrelflecitve RPE irregularity ( Fig 5A) and presence of 
subretinal fluid (Fig 5B) 
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Table 3: Literature review of patients with posterior nodular scleritis: Demographics, clinical features, ultrasonographic features, treatment and 
outcome 
 
 
 
 
 
 
 
 
 
 
 
Study, year Age  
(yrs) 
Gender Laterality  Systemic 
disease  
Pain                                        Clinical Signs 
Anterior 
segment 
Posterior segment Location 
Brod et al, 199024 70 Female Unilateral Nil No N/A Subretinal mass, SRD, disc 
edema, choroidal folds 
Supero-temporal 
Finger et al, 19905 66 Male Unilateral Poly-
arthritis 
Yes CCC Orange subretinal tumour, 
SRD 
Supero-nasal 
Demirci et al, 20003 41 Female Unilateral Nil No Normal Orange subretinal mass, SRD Infero-nasal  
Osman Saatci et al, 
200125 
36 Male Unilateral Nil No Epi 
vessels 
Subretinal mass, SRD N/A 
Wang et al, 200326 40 Female Unilateral Nil No Normal Subretinal mass, retinal 
striae, optic disc edema 
Supero-nasal 
Shukla et al, 200622 45 Female Unilateral Nil Yes Normal Cream-colored lesion, SRD, 
choroidal folds 
Temporal to fovea 
Kranias et al, 200627 60 Female Bilateral N/A N/A Proptosis Nonpigmented choroidal 
mass 
Nasal 
Perez-Campagne et 
al, 200720 
30 Male Unilateral Sarcoid-
osis 
Yes CCC Amelanotic mass  Nasal 
Hage et al, 201114 38        Female             Unilateral Nil Yes         Normal                  Yellow choroidal mass, SRD                               Temporal to fovea      
52 Female Unilateral Nil Yes Normal Yellow lesion with SRD Temporal to macula 
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Study, year                            Ultrasonographic characteristics Treatment Follow-up  Response 
to treatment 
- Lesion Thickness 
(mm) 
          Shape Internal 
echogenicity 
T- sign 
Brod et al, 199024 4 N/A Moderate Yes Oral steroids 4 months Resolution 
Finger et al, 19905 8.3 Multinodular High Yes Enucleation   
Demirci et al, 20003 7.5 Dome-shaped High yes Nil 12 years No change 
Osman Saatci et al, 200125 N/A N/A Moderate Yes Oral steroids 1 year Resolution 
Wang et al, 200326 4.97 Dome-shaped High Yes Oral steroids 7 months Resolution 
Shukala et al, 200622 4.5 Dome-shaped Moderate Yes IV steroids 15 months Resolution 
Kranias et al, 200627 N/A Bi-convex Medium N/A Oral steroids  N/A 
Perez-Campagne et al, 200720 5 Nodular N/A Yes Oral steroids 6 months Resolution 
Hage et al., 201114 4.6                               Dome-shaped   N/A N/A Oral steroids  2 years         Resolution  
N/A Dome-shaped  Topical 
NSAID 
5 months Resolution 
N/A – information not available, SRD- serous retinal detachment, CCC- circum corneal congestion, IV – intravenous, NSAID- Non steroidal anti 
inflammatory drug 
 
Table 4: Clinical characteristics of posterior nodular scleritis  
Gender Female preponderance 
Symptoms Periocular Pain and blurred vision 
Systemic disease Predominantly associated with systemic inflammatory disorder 
Laterality Unilateral 
Location More commonly - Inferotemporal quadrant around equator, can be present in any quadrant 
Associated 
ocular signs 
Anterior scleritis, and conjunctival chemosis 
Ultrasound 
characteristics 
Nodular swelling ,‘T’ sign and subretinal fluid 
Treatment 
response 
Nodular swelling gets smaller but residual swelling often persists but can disappear completely 
 
